Clinical Trial Update: SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating stereotactic body radiotherapy (SBRT) with immunotherapy and atezolizumab-bevacizumab in hepatocellular carcinoma with major portal vei…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: HCC | Phase 2 | Status: RECRUITING